A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Lichen Planopilaris
Latest Information Update: 14 Jul 2026
At a glance
- Drugs Brepocitinib (Primary)
- Indications Lichen planus
- Focus Registrational; Therapeutic Use
- Sponsors Priovant Therapeutics
Most Recent Events
- 20 May 2026 According to Priovant Therapeutics media release, registrational trial of brepocitinib in lichen planopilaris (LPP) enrolled its first subjects in March 2026
- 23 Apr 2026 New trial record